MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte's Flow Electroporation® and ExPERT technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md, Jan. 3, 2023 /PRNewswire/